Bid Evaluation For Drugs/ Medicines (Injectables, Inhalations & IV Fluids) Financial year 2017-18
(Sole Agents of Not Prequalified Items)

BID EVALUATION CRITERIA

Tender Sr. No. 91

Name of Item . Inj. metoprolol 5mg/ 5ml ,amp. Of 5ml, packed in carton with leaflet.

Name of Bidder	Name of firm/ Manufecturer	Brand Name	Compulsory Parameters							Marking Criteria																
			Prequalification, (Preq.),/ Sole Agency Agreement (SAA)/ Drug Sale License ("DSL") / Valid Drug Registration Certificate of the Product (DRC),/ Sample Specifications (SS),/ Undertaking, Regarding non declaration of Spurios Batch by DTL's of Punjab/ any other competent lab. within last three years (Und.T of DTL).							Bidder and Manufecturer Relationship (20)				Local Market Business (How many years the quoted product is being marketed in Pakistan) (25)					Compliance of Quality Standards (20)		International Testing (Reports From WHO ACC. Int. Labs. Performed on the product by any procuring agency) (15)		Export of Quoted Product (20)		Obt. Marks	Approvel of Sample by TSC/ End User (A/R)	Technical Eligibility of Product	Remarks
			Preq. Status by the Govt. (Y/N)	S.A.A. (Y/N)	DSL (Y/N)	DRC (Y/N)	SS (Y/N)	Und. T. of DTL (Y/N)	cGMP (Y/N)	Less Than 01 Year (0)	Upto 02 Years (05)	Upto 05 Years (10)	More Than 05 Years (20)	Less Than 01 Year (0)	Upto 02 Years (05)	Upto 05 Years (10)	Upto 09 Years (20)	More than 09 Years (25)	FDA/ WHO (20)	Others (10)	1-2 Labs (07)	3-4 Labs (15)	Developed countries (3-5=10 Above 05= 20)	Other Countries (01 Mark for Each Country)				
Novartis Pharma Pak.	Cibagergy Switzerland	Lopressor 5mg/ 5ml	NA	Y	Y	AFR	No Sample	Y	Y	20				25					20		7		0		62	Subject to the provision of sample	Subject to the provision of sample	

Total Marks = 100
Qualifying Marks = 60%

Bid Evaluation For Drugs/ Medicines (Injectables, Inhalations & IV Fluids) Financial year 2017-18
(Sole Agents of Not Prequalified Items)

BID EVALUATION CRITERIA

Tender Sr. No. 102

Name of Item . Inj. Fondaparinux Sodium 2.5mg/0.5ml, Prefilled syrringe, packed in carton with leaflet.

Name of Bidder	Name of firm/ Manufecturer	Brand Name	Compulsory Parameters							Marking Criteria																
			Prequalification, (Preq.),/ Sole Agency Agreement (SAA)/ Drug Sale License ("DSL") / Valid Drug Registration Certificate of the Product (DRC),/ Sample Specifications (SS),/ Undertaking, Regarding non declaration of Spurios Batch by DTL's of Punjab/ any other competent lab. within last three years (Und.T of DTL).							Bidder and Manufecturer Relationship (20)				Local Market Business (How many years the quoted product is being marketed in Pakistan) (25)					Compliance of Quality Standards (20)		International Testing (Reports From WHO ACC. Int. Labs. Performed on the product by any procuring agency) (15)		Export of Quoted Product (20)		Obt. Marks	Approvel of Sample by TSC/ End User (A/R)	Technical Eligibility of Product	Remarks
			Preq. Status by the Govt. (Y/N)	S.A.A. (Y/N)	DSL (Y/N)	DRC (Y/N)	SS (Y/N)	Und. T. of DTL (Y/N)	cGMP (Y/N)	Less Than 01 Year (0)	Upto 02 Years (05)	Upto 05 Years (10)	More Than 05 Years (20)	Less Than 01 Year (0)	Upto 02 Years (05)	Upto 05 Years (10)	Upto 09 Years (20)	More than 09 Years (25)	FDA/ WHO (20)	Others (10)	1-2 Labs (07)	3-4 Labs (15)	Developed countries (3-5=10 Above 05= 20)	Other Countries (01 Mark for Each Country)				
GSK Pak.	Glaxo Wellcome Production France (Aspen Notre Dame De Bondeville France)	Arixtra 2.5mg/ 0.5ml	NA	N	N	Y Not Valid	Y	Y	Y	20				25					0		0		0		45	A	Non Responsive , due to short documents	Compulsory parameter not fulfilled

Total Marks = 100
Qualifying Marks = 60%